Pfizer and BioNTech have completed an application for emergency use authorization (EUA) to the Food and Drug Administration (FDA) for a three-dose COVID-19 vaccine regimen for children aged 6 months to under 5 years old.
Pfizer announced the completion of its EUA application on Wednesday, reported multiple outlets.
The companies initially asked the FDA for an EUA in February for a two-dose regimen of its 3-µg COVID-19 vaccine for the age group, but the agency on Feb. 11 postponed its decision on the application until receiving data on three doses. On the same day, Pfizer-BioNTech announced it would delay completing its EUA request until it receives data on the third dose….